Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-blebbistatin is the active S-enantiomer of blebbistatin, a small molecule inhibitor that selectively and reversibly inhibits the ATPase activity of non-muscle myosin II. It binds within the apex of the myosin cleft, stabilizing myosin in an actin-detached state and thereby blocking actomyosin contractility. This compound is widely used as a research tool to study cell motility, cytokinesis, muscle contraction, and related processes dependent on non-muscle myosin II. It does not significantly inhibit smooth muscle myosin II or other classes such as I, V, or X. The drug is highly light-sensitive; exposure to blue light can photoinactivate its inhibitory effect[1][3][4][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-blebbistatin.